Baystate Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $101K | Hold |
527
| – | – | 0.01% | 273 |
|
|
2023
Q3 | $93.3K | Hold |
527
| – | – | 0.01% | 262 |
|
|
2023
Q2 | $100K | Hold |
527
| – | – | 0.01% | 256 |
|
|
2023
Q1 | $106K | Hold |
527
| – | – | 0.01% | 244 |
|
|
2022
Q4 | $125K | Hold |
527
| – | – | 0.01% | 231 |
|
|
2022
Q3 | $105K | Hold |
527
| – | – | 0.01% | 228 |
|
|
2022
Q2 | $77K | Hold |
527
| – | – | 0.01% | 266 |
|
|
2022
Q1 | $86K | Sell |
527
-528
| -50% | -$86.2K | 0.01% | 259 |
|
|
2021
Q4 | $179K | Hold |
1,055
| – | – | 0.02% | 188 |
|
|
2021
Q3 | $199K | Hold |
1,055
| – | – | 0.02% | 151 |
|
|
2021
Q2 | $179K | Hold |
1,055
| – | – | 0.02% | 153 |
|
|
2021
Q1 | $149K | Buy |
+1,055
| New | +$149K | 0.02% | 154 |
|
|
2017
Q1 | – | Sell |
-460
| Closed | -$19K | – | 661 |
|
|
2016
Q4 | $19K | Buy |
+460
| New | +$19K | ﹤0.01% | 234 |
|